The Singular Health (ASX:SHG) share price launched 27% higher today

The Singular Health Group Ltd (ASX: SHG) share price rocketed 27% higher today, but with no news out we cover the recent developments.

| More on:
Two children and a dog get set to launch their friend rocketing high into the sky.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Singular Health Group Ltd (ASX: SHG) share price took flight today, increasing by 27.2% to 51.5 cents a share. However, the recently listed medical imaging technology company had no news out today.

Singular Health has gained a spot on plenty of watchlists over the last couple of weeks. It might be worth recapping what all the fuss is about.

What does Singular Health offer?

The proprietary technology developed by Singular Health enables the viewing of a 3D image, which is compiled of 2D medical images. More specifically, this technology is the company's volumetric rendering platform.

Singular Health notes that this technology provides immersive viewing across a range of medical applications. Such applications include orthodontics, maxilla-facial surgery, oncology, general surgery, and orthopedics.

In addition to this, MedVR is Singular Health's product which allows the viewing of scans through an interactive virtual reality experience.

The company derives its revenue from both initial hardware sales and subscription payments on an on-going basis for the use of software, commonly referred to a software-as-a-service (SaaS).

Recent Singular Health developments affecting the share price

With Singular Health being a small and upcoming player in a fairly competitive space, shareholders would be looking for progress. On Monday, shareholders got exactly that. The company announced that it had received a purchase order totalling $170,000 for development of GeoVR software.

The order was received from FlowCentric Technologies, with which Singular Health is also in the process of finalising a joint venture. The purchase order will enable FlowCentric to conduct a pilot program using Singular Health's GeoVR software.

You might be thinking, well this a world away from medical imaging. And you'd be correct. But the volumetric rendering technology developed by Singular Health spans multiple use cases. In this instance, it will be used to develop a commercially viable product that utilises imaging and predictive technologies for mining and exploration.

FlowCentric currently services over 350,000 users with its business process management software. These include a number of global resource companies.

For further progress on the medical imaging front, shareholders will have to wait a little longer to see that play out.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Green stock market graph with a rising arrow symbolising a rising share price.
Opinions

3 unstoppable ASX shares to buy with $3,000

These businesses have strong futures.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to buy these shares.

Read more »

A senior couple sets at a table looking at documents as a professional looking woman sits alongside them as if giving retirement and investing advice.
Share Market News

Nickel Industries posts Q4 earnings and lifts outlook

Nickel Industries reports lower December quarter EBITDA.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Share Market News

Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028

Neuren Pharmaceuticals has projected DAYBUE global net sales to hit US$700 million by 2028.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

Why Bell Potter just upgraded this ASX All Ords share to a buy rating

The broker has turned bullish on this growing company. Here's what you need to know.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Bell Potter says these ASX shares are best buys in January

The broker has good things to say about these shares.

Read more »

A woman stands at her desk looking a her phone with a panoramic view of the harbour bridge in the windows behind her with work colleagues in the background.
Share Market News

Should I invest $1,000 in the VGS ETF?

With $1,000 to invest, diversification matters. This Vanguard ETF provides instant exposure to global markets outside Australia.

Read more »

Close up of a sad young woman reading about declining share price on her phone.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »